Saturday, October 17, 2026 · Edition updated 6:00 AM ETSAT, OCT 17 · 6 AM ET editionNext edition in Next --:--:--

A planned trial of sirolimus in women with a higher Alzheimer's risk gene

Recruiting · PHASE 1 · University of Missouri-Columbia

What this means

This is a planned study that has not reported results yet. It will test whether a daily pill called sirolimus can improve blood flow and energy use in the brain.

Plain-English summary written by an AI model from the registry listing.

Status
Recruiting
Who can join
Ages 45–65
Where
1 site, including Missouri

Contacts and how to join ↗

The science

Registered title
Effects of Sirolimus on Asymptomatic ApoE4 Carriers
Phase
PHASE 1
Study type
interventional
Conditions
Genetic Predisposition to Disease, Healthy Volunteer, APOE-4 Positive
What is tested
Sirolimus (rapamycin), Placebo
Sponsor
University of Missouri-Columbia
Ages
45 Years to 65 Years
Dates
First posted Jul 27, 2026 · updated Oct 5, 2026

Registry summary

Alzheimer's disease is a devastating neurodegenerative disease characterized by accumulation of clumps (also called plaques) and bundles of fibers (also called tangles) in the brain, for which there is currently no cure.

Sirolimus (Rapamycin) is an FDA-approved medication which may improve the blood flow to the brain. The purpose of the clinical trial is to find out whether sirolimus can help improve blood flow and energy use in the brain in women ages 45 to 65 who have the ApoE4 gene, a gene which increases the risk of developing Alzheimer's disease later in life.

There will be two arms in this trail, a sirolimus arm and a placebo arm. A placebo is a pill that looks like the study drug, but it does not have any real medicine in it. Participants will be randomized to one arm or the other, but not to both arms. Three study visits over a 12-week period are required.

Participants will: (i) Complete some questionnaires about how well you think; (ii) Complete genetic testing for the ApoE4 gene; (iii) Have blood work, blood pressure and height and weight collected; (iv) Take either Sirolimus or a placebo daily, by mouth, for approximately 4 weeks; (v) Keep a diary of when the sirolimus or placebo is taken; (vi) Complete 2 Magnetic Resonance Imaging (MRI) exams

Sites (1)

  • University of Missouri, Columbia, Missouri, United States

Related treatments

Rapamycin

More aging trials in these states

Missouri

Report a problem